Weleader Biomedical CoROCO:7713 -1.54%47 EBITDA Margin % is 36.38% as of Dec. 2025, which is 17% above its 10-year median of 31.09. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 94.11% on this metric.
Weleader Biomedical Co (ROCO:7713) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Weleader Biomedical Co EBITDA Margin % Related Terms
Weleader Biomedical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Weleader Biomedical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7713 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Weleader Biomedical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a EBITDA Margin % of 36.38% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Weleader Biomedical Co and its competitors. This is 17% above median its historical median of 31.09. Over the past decade, Weleader Biomedical Co's EBITDA Margin % has ranged from 26.57 to 35.44. According to the industry distribution chart, Weleader Biomedical Co ranks #48 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 5.9%.
Is Weleader Biomedical Co's EBITDA Margin % too high?
Weleader Biomedical Co's current EBITDA Margin % of 36.38% is 17% above median its 10-year median of 31.09. Over the past 10 years, this metric has ranged from a low of 26.57 to a high of 35.44. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Weleader Biomedical Co's value of 36.38% is 387% above this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #48 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #48 out of 815 companies for EBITDA Margin %. This places Weleader Biomedical Co in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Weleader Biomedical Co's value of 36.38% is 387% above this benchmark. Historically, Weleader Biomedical Co's own EBITDA Margin % has ranged from 26.57 to 35.44 over the past decade. While the company's 10-year median is 31.09 vs. the industry median of 7.47, Weleader Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current EBITDA Margin % of 36.38% is 387% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current EBITDA Margin % is 36.38%, which is 17% above median its own 10-year median of 31.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current EBITDA Margin % of 36.38%. The current EBITDA Margin % is 36.38%, which is 17% above median its 10-year median of 31.09 and 387% above the Medical Devices & Instruments industry median of 7.47. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current EBITDA Margin % is 36.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score
Get the complete analysis for ROCO:7713
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
